Heart failure & cardiomyopathiesRandomised controlled trial

Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomized clinical trial

Eur J Heart FailPublished

  • Randomised controlled trial
  • phase II
  • multicentre
  • placebo-controlled
  • open-label extension

Authors' conclusion

In patients with HFpEF and ID without ID-anaemia, FCM did not improve exercise hemodynamics, LV diastolic function, myocardial or skeletal energy homeostasis.

Study context

Population
Patients with heart failure with preserved ejection fraction (HFpEF) (LVEF ≥50%) and iron deficiency without iron deficiency (ID)-anaemia, NYHA class II–III
Participants
45 patients
Comparison
Ferric carboxymaltose vs placebo
Primary endpoint
Pulmonary capillary wedge pressure during multiple levels of exercise
Follow-up
4 months

Primary result

As reported in the abstract

Pulmonary capillary wedge pressure during exercise

Mean change

−1.0 mmHg

95% CI −4 to 2

P = 0.52

FCM vs Placebo
mean change −1.0 mmHg (95% CI −4 to 2); P = 0.52

Further findings

OutcomeFCMPlaceboEstimateP value
RVEF+4 (SD 5) %−3 (SD 6) %P = 0.002
Acetylcholine-mediated microvascular perfusion+5 (SD 24) a.u.−16 (SD 25) a.u.P = 0.04
6MWD+6 (SD 31) m−13 (SD 31) mP = 0.06
6MWD · after correction for baseline differences+28 mP = 0.01

Myocardial PCr/ATP ratio, calf muscle PCr recovery time, NT-proBNP, KCCQ

No change in myocardial PCr/ATP ratio
P = 0.18
No change in calf muscle PCr recovery time
P = 0.11
No change in NT-proBNP
P = 0.78
No change in KCCQ
P = 0.67

Original publication

Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomized clinical trial. Eur J Heart Fail. Published 18 May 2026. doi:10.1093/ejhf/xuag162

Summarised from the published abstract; every number is checked against it